13.57% -0.1796

Avenue Therapeutics Inc (ATXI)

Überblick Nachrichten Preisverlauf Financials Warum fällt ATXI? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1174)

Biotechnology (661)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ATXI's Discussions on Twitter

Vergleichen Sie ATXI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXI Avenue Therapeutics Inc	0.2404	0	0	-10.38M	-12.45M	-3.81
VRTX Vertex Pharmaceuticals Inc	441.30	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	521.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.83	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.14	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	241.20	28.51B	3.81B	-644.79M	-669.77M	-6.24

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Vergleichen Sie ATXI mit anderen Aktien

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider

Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World

Yousif Capital Management LLC Has $1.99 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 156.3% in May - Defense World

Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World

NBC Securities Inc. Takes $31,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World

60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen - Defense World

Park Avenue Securities LLC Has $713,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Rhumbline Advisers Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Autolus Therapeutics’ (AUTL) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Park Avenue Securities LLC Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

NBC Securities Inc. Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World

Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World

Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World

Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jane Street Group LLC Increases Stock Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Defense World

Public Employees Retirement System of Ohio Invests $137,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World

New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms - The Daily Jeffersonian

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline – FBIO - ACCESS Newswire

BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World

37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World

TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World

AJ201 shows good safety, hints of efficacy in SBMA clinical trial - SMA News Today

Annji Pharmaceutical Company Announces Positive Phase 1/2A Results for Aj201 in Spinal and Bulbar Muscular Atrophy Patients - marketscreener.com

NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - The Globe and Mail

StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World

Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Avenue Therapeutics Ends License Agreement with AnnJi - TipRanks

Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider

Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider

Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews

CBLI Back On Track, HTBX Joins Hands With OncoSec, PRAH In Good Health - RTTNews

Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com

SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow

AVENUE THERAPEUTICS, INC. SEC 10-K Report - TradingView

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - The Manila Times

Oncotelic Therapeutics Publishes New Research Demonstrating - GlobeNewswire

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ATXI